# This super composite rating is the result of a weighted average of the rankings based on the following ratings.

*biotech · news · 2026-05-28 · MarketScreener*

## Key points

- The Trader super rating uses a four-month window for EPS Revisions as a key factor.
- Investor super rating uniquely integrates a one-year EPS Revisions measure, differing from Trader's methodology.
- The Global rating requires coverage from at least four of five distinct composite sub-ratings for calculation.
- Quality composite rating calculation only proceeds if the company is covered by at least two sub-ratings.

Trader This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Investor This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions. Global This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions. Quality This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

[Read the full story on MarketScreener](https://www.marketscreener.com/news/renovorx-gets-fda-orphan-drug-designation-for-oxaliplatin-to-treat-pancreatic-cancer-ce7f5ddada8cf624)

---

Canonical: https://newsio.io/n/74f51284-c7c7-4608-973a-40c7e9e7ce11/this-super-composite-rating-is-the-result-of-a-weighted-average-of-the-rankings
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works